United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - simvastatin 10 mg - simvastatin tablets usp are indicated: - to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. - as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c): in adults with primary hyperlipidemia. in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to other ldl-c-lowering therapies to reduce ldl-c in adults with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. hypertriglyceridemia. simvastatin tablets are contraindicated in the following conditions: - concomitant use of strong cyp3a4 inhibitors (sel

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - capreomycin sulfate (unii: 9h8d3j7v21) (capreomycin - unii:232hyx66hc) - capreomycin for injection, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of m. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of m. tuberculosis .

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection, usp is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - dactinomycin (unii: 1cc1jfe158) (dactinomycin - unii:1cc1jfe158) - dactinomycin for injection is indicated for the treatment of adult and pediatric patients with wilms tumor, as part of a multi-phase, combination chemotherapy regimen. dactinomycin for injection is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. dactinomycin for injection is indicated for the treatment of adult and pediatric patients with ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. dactinomycin for injection is indicated for the treatment of adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. dactinomycin for injection is indicated for the treatment of post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. dactinomycin for injection is indicated for the treatment of adult patients with locally recurrent or locoregional s

United States - English - NLM (National Library of Medicine)

hisun pharmaceuticals usa, inc. - cladribine (unii: 47m74x9yt5) (cladribine - unii:47m74x9yt5) - cladribine injection, usp is indicated for the treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. cladribine injection, usp is contraindicated in those patients who are hypersensitive to this drug or any of its components.

United States - English - NLM (National Library of Medicine)

hisun pharmaceuiticals usa, inc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets usp are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablets usp are indicated to: - reduce the risk of total mortality by reducing coronary death. - reduce the risk of mi. - reduce the risk of undergoing myocardial revascularization procedures. - reduce

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - simvastatin 10mg - film coated tablet - 10 mg - active: simvastatin 10mg excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - simvastatin 20mg - film coated tablet - 20 mg - active: simvastatin 20mg excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - simvastatin 40mg - film coated tablet - 40 mg - active: simvastatin 40mg excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - simvastatin 5mg - film coated tablet - 5 mg - active: simvastatin 5mg excipient: butylated hydroxyanisole hyprolose hypromellose iron oxide yellow lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide